PreprintArticleVersion 1Preserved in Portico This version is not peer-reviewed
Exploring p53 Protein Expression and Its Link to TP53 Mutation in Myelodysplasia-Related Malignancies - Interpretive Challenges and Potential Field of Applications
Version 1
: Received: 31 August 2023 / Approved: 1 September 2023 / Online: 4 September 2023 (07:23:19 CEST)
How to cite:
Bedekovics, J.; Madarász, K.; Mokánszki, A.; Molnár, S.; Mester, Á.; Miltényi, Z.; Méhes, G. Exploring p53 Protein Expression and Its Link to TP53 Mutation in Myelodysplasia-Related Malignancies - Interpretive Challenges and Potential Field of Applications. Preprints2023, 2023090117. https://doi.org/10.20944/preprints202309.0117.v1
Bedekovics, J.; Madarász, K.; Mokánszki, A.; Molnár, S.; Mester, Á.; Miltényi, Z.; Méhes, G. Exploring p53 Protein Expression and Its Link to TP53 Mutation in Myelodysplasia-Related Malignancies - Interpretive Challenges and Potential Field of Applications. Preprints 2023, 2023090117. https://doi.org/10.20944/preprints202309.0117.v1
Bedekovics, J.; Madarász, K.; Mokánszki, A.; Molnár, S.; Mester, Á.; Miltényi, Z.; Méhes, G. Exploring p53 Protein Expression and Its Link to TP53 Mutation in Myelodysplasia-Related Malignancies - Interpretive Challenges and Potential Field of Applications. Preprints2023, 2023090117. https://doi.org/10.20944/preprints202309.0117.v1
APA Style
Bedekovics, J., Madarász, K., Mokánszki, A., Molnár, S., Mester, Á., Miltényi, Z., & Méhes, G. (2023). Exploring p53 Protein Expression and Its Link to TP53 Mutation in Myelodysplasia-Related Malignancies - Interpretive Challenges and Potential Field of Applications. Preprints. https://doi.org/10.20944/preprints202309.0117.v1
Chicago/Turabian Style
Bedekovics, J., Zsófia Miltényi and Gábor Méhes. 2023 "Exploring p53 Protein Expression and Its Link to TP53 Mutation in Myelodysplasia-Related Malignancies - Interpretive Challenges and Potential Field of Applications" Preprints. https://doi.org/10.20944/preprints202309.0117.v1
Abstract
Background: TP53 alterations have a significant prognostic effect in myeloid neoplasms. Our objective was to investigate the TP53 gene mutation status, p53 protein expression, and their re-lationship in dysplasia-related myeloid neoplasms with varying levels of myeloblast counts. Methods: 76 bone marrow biopsy samples with different blast counts were analyzed. Total and strong (3+) p53 expression was determined. Dual immunohistochemical staining was performed to determine the cell population associated with p53 expression. NGS analysis was performed using the Accel-Amplicon Comprehensive TP53 panel. Results: Both p53 expression and TP53 VAF showed a significant correlation with the myeloblast ratio (p<0.0001), however, p53 expres-sion was present in other cell lineages as well. The VAF value exhibited a significant correlation with p53 expression. A high specificity (0.9800) was observed for TP53 mutation using the ≥10% strong (3+) p53 cut-off value, although the sensitivity (0.4231) was low. Conclusion: Strong (3+) p53 expression using a ≥10% cut-off value accurately predicts TP53 mutation but doesn't reveal the allelic state. The p53 expression is significantly influenced by myeloblast count, and histo-logical interpretation should consider the presence of intermixed non-neoplastic marrow cells with varying physiological p53 expression.
Keywords
p53 expression; TP53 mutation; myelodysplasia; myeloblast; bone marrow
Subject
Medicine and Pharmacology, Pathology and Pathobiology
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
,
